160 related articles for article (PubMed ID: 34609771)
1. Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination.
Triwatcharikorn J; Puaratana-Arunkon T; Punyaratabandhu P; Mongkolpathumrat P; Palapinyo S; Buranapraditkul S; Rerknimitr P; Klaewsongkram J
Clin Exp Dermatol; 2022 Apr; 47(4):735-738. PubMed ID: 34609771
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study.
Cebeci Kahraman F; Savaş Erdoğan S; Aktaş ND; Albayrak H; Türkmen D; Borlu M; Arıca DA; Demirbaş A; Akbayrak A; Polat Ekinci A; Gökçek GE; Çelik HA; Taşolar MK; An İ; Temiz SA; Hazinedar E; Ayhan E; Hızlı P; Solak EÖ; Kılıç A; Yılmaz E
J Cosmet Dermatol; 2022 Sep; 21(9):3692-3703. PubMed ID: 35780311
[TBL] [Abstract][Full Text] [Related]
3. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
4. Development of immediate and chronic spontaneous urticaria following mRNA COVID-19 vaccination: Tolerability of revaccination and immunological study.
Teo RXW; Leung BPL; Thong BY; Tan JWL; Chan GYL; Lim XR
Ann Acad Med Singap; 2024 Jan; 53(1):57-59. PubMed ID: 38920217
[No Abstract] [Full Text] [Related]
5. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of immune response profile in patients with immediate allergic and autoimmune urticarial reactions induced by SARS-CoV-2 vaccines.
Wang CW; Chen CB; Lu CW; Chen WT; Hui RC; Chiu TM; Chi MH; Lin JC; Huang YH; Chang YC; Wu J; Chen KY; Lin YY; Ger TY; Lin JY; Tsai WT; Pan YJ; Chung WH
J Autoimmun; 2023 Jul; 138():103054. PubMed ID: 37245259
[TBL] [Abstract][Full Text] [Related]
7. Urticaria 12 Days After COVID-19 mRNA Booster Vaccination.
Wolfson AR; Freeman EE; Blumenthal KG
JAMA; 2022 May; 327(17):1702-1703. PubMed ID: 35420647
[No Abstract] [Full Text] [Related]
8. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
[No Abstract] [Full Text] [Related]
9. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC;
Front Immunol; 2022; 13():918896. PubMed ID: 35757764
[TBL] [Abstract][Full Text] [Related]
11. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
[TBL] [Abstract][Full Text] [Related]
13. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity.
Kara Z; Akçin R; Demir AN; Dinç HÖ; Taşkın HE; Kocazeybek B; Yumuk VD
Obes Surg; 2022 Sep; 32(9):2987-2993. PubMed ID: 35802279
[TBL] [Abstract][Full Text] [Related]
14. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK
BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305
[TBL] [Abstract][Full Text] [Related]
15. Disease activity of patients with chronic urticaria receiving COVID-19 vaccines.
Tuchinda P; Kulthanan K; Chularojanamontri L; Pongkittilar B; Pochanapan O; Rujitharanawong C
Asian Pac J Allergy Immunol; 2024 Jun; 42(2):123-131. PubMed ID: 36278777
[TBL] [Abstract][Full Text] [Related]
16. CoronaVac/Sinovac COVID-19 Vaccine-Related Hypersensitivity Reactions and Second-Dose Vaccine Administration: Tertiary Allergy Center Experience.
Gumusburun R; Dalgıc CT; Mete Gokmen EN; Sin AZ
Int Arch Allergy Immunol; 2022; 183(7):778-784. PubMed ID: 35462361
[TBL] [Abstract][Full Text] [Related]
17. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination.
Pitlick MM; Joshi AY; Gonzalez-Estrada A; Chiarella SE
Allergy Asthma Proc; 2022 Jan; 43(1):40-43. PubMed ID: 34983709
[No Abstract] [Full Text] [Related]
18. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 vaccine-associated subacute thyroiditis.
Yorulmaz G; Sahin Tekin M
J Endocrinol Invest; 2022 Jul; 45(7):1341-1347. PubMed ID: 35182366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
